Agenus (NASDAQ:AGEN) Given New $30.00 Price Target at HC Wainwright

Agenus (NASDAQ:AGEN) had its target price upped by equities research analysts at HC Wainwright from $23.00 to $30.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential upside of 348.36% from the company’s current price.

Several other brokerages have also recently commented on AGEN. Wall Street Zen raised shares of Agenus from a “hold” rating to a “buy” rating in a research report on Monday, April 6th. Weiss Ratings reiterated a “sell (d)” rating on shares of Agenus in a research note on Tuesday, June 16th. Finally, Zacks Research lowered Agenus from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $30.00.

Agenus Stock Performance

Shares of AGEN traded up $3.34 during mid-day trading on Monday, hitting $6.69. 158,384,110 shares of the company’s stock were exchanged, compared to its average volume of 1,941,208. The company has a market cap of $278.61 million, a price-to-earnings ratio of 4.21 and a beta of 1.55. Agenus has a fifty-two week low of $2.71 and a fifty-two week high of $8.70. The stock’s 50-day moving average is $3.31 and its 200-day moving average is $3.42.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings data on Monday, May 11th. The biotechnology company reported $1.02 earnings per share for the quarter, missing analysts’ consensus estimates of $2.10 by ($1.08). Agenus had a net margin of 50.49% and a negative return on equity of 31.66%. The business had revenue of $33.74 million during the quarter, compared to analyst estimates of $129.50 million. As a group, equities research analysts anticipate that Agenus will post 0.02 EPS for the current year.

Hedge Funds Weigh In On Agenus

A number of institutional investors have recently modified their holdings of AGEN. Invesco Ltd. acquired a new stake in shares of Agenus in the 1st quarter worth $88,000. AQR Capital Management LLC raised its holdings in Agenus by 3,080.3% during the first quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock worth $664,000 after purchasing an additional 427,604 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in Agenus in the first quarter valued at about $58,000. JPMorgan Chase & Co. lifted its position in Agenus by 608.0% in the second quarter. JPMorgan Chase & Co. now owns 78,637 shares of the biotechnology company’s stock valued at $359,000 after purchasing an additional 67,530 shares during the period. Finally, Marshall Wace LLP purchased a new stake in Agenus in the 2nd quarter valued at approximately $1,976,000. 61.46% of the stock is owned by institutional investors and hedge funds.

Agenus News Summary

Here are the key news stories impacting Agenus this week:

• Positive Sentiment: Agenus entered an oversubscribed private placement that brings in about $85 million upfront, with up to $255 million more possible if warrants are exercised, giving the company a potential $340 million total financing package. Article Title
• Positive Sentiment: The new funding is intended to support the registrational Phase 3 ROBBIN trial of botensilimab plus balstilimab in MSS colon cancer, which investors may view as a clearer and more valuable development path. Article Title
• Neutral Sentiment: Management said the cash runway could extend into 2027 even without warrant exercise, and potentially longer if the warrants are fully exercised, reducing near-term financing risk. Article Title
• Neutral Sentiment: Agenus also said it plans to stop funding the BATTMAN metastatic colorectal cancer study, signaling a strategic pivot away from that program and toward ROBBIN. Article Title
• Negative Sentiment: The BATTMAN cutback could be seen as a sign of prioritization under financial constraints, and the company still depends on future clinical progress to justify the sharp share-price jump. Article Title

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.